Table: Santen Pharm -6-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

08/11/2022 06:00

Nov 8 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended        Year to  
                  Sep 30, 2022        Sep 30, 2021      Mar 31, 2023  
                     LATEST             YEAR-AGO           COMPANY    
                     RESULTS             RESULT           FORECAST    
  Sales              128.92              128.76            280.00     
                   (+0.1 pct)          (+8.3 pct)        (+5.2 pct)   
  Operating        loss 19.02             18.81              4.00     
                                       (+0.6 pct)        (-88.9 pct)  
  Pretax           loss 19.10             18.39              3.00     
                                       (+0.2 pct)        (-91.6 pct)  
  Net              loss 22.04             14.31                       
                                       (+3.6 pct)                     
  EPS Basic      loss 56.05 yen         35.79 yen      loss 14.20 yen 
  EPS Diluted    loss 56.05 yen         35.73 yen                     
  Ann Div                               32.00 yen         32.00 yen   
  -Q2 Div           16.00 yen           16.00 yen                     
  -Q4 Div                               16.00 yen         16.00 yen   
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T